[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL127496A0 - The use of MMP inhibitors for the treatment of ocular angiogenesis - Google Patents

The use of MMP inhibitors for the treatment of ocular angiogenesis

Info

Publication number
IL127496A0
IL127496A0 IL12749698A IL12749698A IL127496A0 IL 127496 A0 IL127496 A0 IL 127496A0 IL 12749698 A IL12749698 A IL 12749698A IL 12749698 A IL12749698 A IL 12749698A IL 127496 A0 IL127496 A0 IL 127496A0
Authority
IL
Israel
Prior art keywords
treatment
mmp inhibitors
ocular angiogenesis
angiogenesis
ocular
Prior art date
Application number
IL12749698A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL127496A0 publication Critical patent/IL127496A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
IL12749698A 1997-12-19 1998-12-10 The use of MMP inhibitors for the treatment of ocular angiogenesis IL127496A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6826197P 1997-12-19 1997-12-19

Publications (1)

Publication Number Publication Date
IL127496A0 true IL127496A0 (en) 1999-10-28

Family

ID=22081436

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12749698A IL127496A0 (en) 1997-12-19 1998-12-10 The use of MMP inhibitors for the treatment of ocular angiogenesis

Country Status (9)

Country Link
EP (1) EP0930067A3 (hu)
JP (2) JPH11263735A (hu)
KR (1) KR19990063202A (hu)
AU (1) AU761585B2 (hu)
CA (1) CA2256303A1 (hu)
HU (1) HUP9802971A1 (hu)
IL (1) IL127496A0 (hu)
NZ (1) NZ333457A (hu)
ZA (1) ZA9811629B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT977733E (pt) * 1997-02-03 2003-12-31 Pfizer Prod Inc Derivados de acido arilsulfonilamino-hidroxamico
BR9814643A (pt) 1997-11-14 2000-10-03 Searle & Co Inibidor de metaloprotease de ácido sulfona hidroxâmico aromático
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6337340B1 (en) * 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
EE200100410A (et) 1999-02-08 2002-12-16 G.D. Searle & Co. Sulfamaathüdroksaamhappe metalloproteaasi inhibiitor
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2001070696A1 (fr) * 2000-03-21 2001-09-27 Ishihara Sangyo Kaisha, Ltd. Derives de nitroethenamine ou sels desdits composes, et compositions pharmaceutiques contenant ces derives ou ces sels
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
CA2444704C (en) 2001-04-23 2012-07-10 University Of Virginia Patent Foundation Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
WO2002092588A2 (en) 2001-05-11 2002-11-21 Pharmacia Corporation Aromatic sulfone hydroxamates and their use as protease inhibitors
DK1423115T3 (da) * 2001-08-06 2009-06-15 Childrens Medical Center Nitrogen-substituerede thalidomidanalogers antiangiogenetiske aktivitet
US7119203B2 (en) 2002-04-25 2006-10-10 Pharmacia Corporation Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2004080452A1 (ja) * 2003-03-10 2004-09-23 Shionogi & Co., Ltd. 網膜疾患治療薬
GB0326546D0 (en) * 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
US20090018094A1 (en) * 2006-12-01 2009-01-15 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
WO1997041844A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
CA2285372A1 (en) * 1997-04-01 1998-10-08 Melwyn A. Abreo Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
GB9707333D0 (en) * 1997-04-11 1997-05-28 British Biotech Pharm Metalloproteinase inhibitors

Also Published As

Publication number Publication date
AU761585B2 (en) 2003-06-05
CA2256303A1 (en) 1999-06-19
HU9802971D0 (en) 1999-02-01
JPH11263735A (ja) 1999-09-28
JP2001122775A (ja) 2001-05-08
EP0930067A2 (en) 1999-07-21
ZA9811629B (en) 2000-06-19
HUP9802971A1 (hu) 2000-08-28
KR19990063202A (ko) 1999-07-26
NZ333457A (en) 2001-06-29
AU9722498A (en) 1999-07-08
EP0930067A3 (en) 1999-09-15

Similar Documents

Publication Publication Date Title
IL127496A0 (en) The use of MMP inhibitors for the treatment of ocular angiogenesis
HK1042475A1 (zh) 用於治療炎癥的取代噻唑
SG100767A1 (en) Sulfonamides for treatment of endothelin-mediated disorders
AP9901677A0 (en) Substituted benzopyran derivatives for the treatment of inflammation
EP1115422A4 (en) USE OF NON-PEPTIDYLIC COMPOUNDS FOR THE TREATMENT OF INSULIN-RELATED CONDITIONS
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU3187595A (en) Compounds for the treatment of restenosis
GB9725114D0 (en) Treatment of pruritus
HK1022267A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU9278598A (en) Use of azole derivatives for the treatment of inflammatory skin conditions
IL130831A0 (en) Imino-aza-anthracylinone derivatives for the treatment of amyloidosis
AU8626398A (en) Inhibitors of the phosphodiesterase-4 for the treatment of allergic rhinitis
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
IL123422A0 (en) Use of 7alpha-methyl-17alpha-ethynyl-estrane derivatives for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis
GB9926985D0 (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases
SI1068184T1 (en) N-aryloxyethylamine derivatives for the treatment of depression
ID24521A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
GB2322623B (en) Treatment of liquid
SI1133290T1 (en) Use of inhibitors of acetylcholinesterase for the treatment of deliriums
SI1068199T1 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
GB9704212D0 (en) Treatment of liquid
GB9612593D0 (en) Beta3-adrenoceptor agonists for the treatment of hypertension